


CLAIMS

1. A compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein:

W is O, N-H, N-(C₁-C₁₀ alkyl) or S;

each X is independently CH or N;

R¹ is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O;


R² is LY;

each L is a direct bond, C₁-C₁₀ alkylene, C₂-C₁₀ alkenylene or C₂-C₁₀ alkynylene;

Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and


each R³ is independently H, C₁-C₁₀ alkyl, halogen, fluoro C₁-C₁₀ alkyl, O- C₁-C₁₀ alkyl, NH-C₁-C₁₀ alkyl, S-C₁-C₁₀ alkyl, O-fluoro C₁-C₁₀ alkyl, NH-acyl, NH-C(O)-NH-C₁-C₁₀ alkyl, C(O)-NH-C₁-C₁₀ alkyl, aryl or heteroaryl.

2. The compound according to claim 1, wherein R¹ is represented by any of the following structures:



3. The compound according to claim 1 or 2, wherein R¹ is morpholine.
4. The compound according to any one of the preceding claims, wherein W is O or S.
5. The compound according to any one of the preceding claims, wherein W is O.

6. The compound according any one of the preceding claims, wherein X is CH.
7. The compound according to any one of the preceding claims, wherein R^3 is H.
8. The compound according to any one of the preceding claims, wherein L is C_1 - C_{10} alkylene.
9. The compound according to claim 8, wherein L is methylene.
10. The compound according to any one of the preceding claims, wherein Y contains one or two heteroatoms.
11. The compound according to claim 10, wherein Y contains two heteroatoms.
12. The compound according to any one of the preceding claims, wherein Y is selected from:



wherein:

A is selected from O, S, NR^4 or optionally substituted C_1 - C_3 alkylene, C_2 - C_3 alkenylene or C_2 - C_3 alkynylene;

W is NR^4 , O or CH_2 ;

wherein R^4 is H or optionally substituted C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl or C_2 - C_{10} alkynyl;

p is selected from 0 or 1;


each m is independently selected from 0, 1 or 2; and

each n is independently selected from 1, 2 or 3.

13. The compound according to claim 11, wherein A is O or C_1 - C_3 alkylene.
14. The compound according to claim 13, wherein A is methylene.
15. The compound according to any one of claims 12 to 14, wherein W is O or CH_2 .

16. The compound according to claim 15, wherein W is O.

17. A compound according to any one of the preceding claims, which is illustrated by any one of the following structures:



18. A pharmaceutical composition comprising a compound according to any one of the preceding claims, and a pharmaceutically acceptable excipient.

19. Use of a compound or composition according to any one of claims 1 to 18, in the manufacture of a medicament for use in the therapeutic treatment of cancer (in particular leukaemia or a PTEN-negative solid tumour), an immune disorder, an inflammatory disorder, or rheumatoid arthritis; in which inhibition of class IA phosphoinositide 3-kinase enzyme is beneficial.

20. Use of a compound or composition according to any one of claims 1 to 18, in the manufacture of a medicament for anti-rejection therapy, in which inhibition of class IA phosphoinositide 3-kinase enzyme is beneficial, wherein the medicament is to be administered to a subject following an organ transplant.